Pulmonary Arterial Hypertension Market Size Forecast Report, 2027 

Pulmonary Arterial Hypertension Market - By Drug Class (Prostacyclin And Prostacyclin Analogs, Soluble Guanylate Cyclase Stimulators, Endothelin Receptor Antagonist, Phosphodiesterase 5, Vasodilators), By Route of Administration & Forecast, 2021-2027

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology 

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; working

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; Data validation

1.5&nbsp;&nbsp;&nbsp; Data sources

1.5.1&nbsp;&nbsp;&nbsp; Secondary

1.5.1.1&nbsp;&nbsp;&nbsp; Paid sources

1.5.1.2&nbsp;&nbsp;&nbsp; Unpaid sources

1.5.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Pulmonary arterial hypertension industry 3600 synopsis, 2016 - 2027

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Drug class trends

2.1.3&nbsp;&nbsp;&nbsp; Route of administration trends

2.1.4&nbsp;&nbsp;&nbsp; Regional trends

Chapter 3&nbsp;&nbsp;&nbsp;Pulmonary Arterial Hypertension Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry segmentation

3.2&nbsp;&nbsp;&nbsp; Industry landscape, 2016 &ndash; 2027 (USD Million)

3.3&nbsp;&nbsp;&nbsp; Industry impact factors

3.3.1&nbsp;&nbsp;&nbsp; Growth drivers

3.3.1.1&nbsp;&nbsp;&nbsp; Increase in prevalence of pulmonary arterial hypertension

3.3.1.2&nbsp;&nbsp;&nbsp; Strong product pipeline

3.3.1.3&nbsp;&nbsp;&nbsp; Growing government initiatives

3.3.1.4&nbsp;&nbsp;&nbsp; Rising global geriatric population

3.3.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.3.2.1&nbsp;&nbsp;&nbsp; Patent expiration

3.3.2.2&nbsp;&nbsp;&nbsp; Side effects associated with the drugs

3.4&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4.1&nbsp;&nbsp;&nbsp; By drug class

3.4.2&nbsp;&nbsp;&nbsp; By route of administration

3.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; Competitive landscape, 2020

3.7.1&nbsp;&nbsp;&nbsp; Company matrix analysis, 2020

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Pulmonary Arterial Hypertension Market, By Drug Class 

4.1&nbsp;&nbsp;&nbsp; Key segment trends

4.2&nbsp;&nbsp;&nbsp; Prostacyclin and prostacyclin analogs

4.2.1&nbsp;&nbsp;&nbsp; Market size, by region, 2016 &ndash; 2027 (USD Million)

4.3&nbsp;&nbsp;&nbsp; Soluble guanylate cyclase (SGC) stimulators

4.3.1&nbsp;&nbsp;&nbsp; Market size, by region, 2016 &ndash; 2027 (USD Million)

4.4&nbsp;&nbsp;&nbsp; Endothelin receptor antagonist (ERA)

4.4.1&nbsp;&nbsp;&nbsp; Market size, by region, 2016 - 2027 (USD Million)

4.5&nbsp;&nbsp;&nbsp; Phosphodiesterase 5 (PDE-5)

4.5.1&nbsp;&nbsp;&nbsp; Market size, by region, 2016 - 2027 (USD Million)

4.6&nbsp;&nbsp;&nbsp; Vasodilators

4.6.1&nbsp;&nbsp;&nbsp; Market size, by region, 2016 - 2027 (USD Million)

4.7&nbsp;&nbsp;&nbsp; Others

4.7.1&nbsp;&nbsp;&nbsp; Market size, by region, 2016 - 2027 (USD Million)

Chapter 5&nbsp;&nbsp;&nbsp;Pulmonary Arterial Hypertension Market, By Drug Class 

5.1&nbsp;&nbsp;&nbsp; Key segment trends

5.2&nbsp;&nbsp;&nbsp; Oral

5.2.1&nbsp;&nbsp;&nbsp; Market size, by region, 2016 &ndash; 2027 (USD Million)

5.3&nbsp;&nbsp;&nbsp; Intravenous

5.3.1&nbsp;&nbsp;&nbsp; Market size, by region, 2016 &ndash; 2027 (USD Million)

5.4&nbsp;&nbsp;&nbsp; Inhalation

5.4.1&nbsp;&nbsp;&nbsp; Market size, by region, 2016 - 2027 (USD Million)

Chapter 6&nbsp;&nbsp;&nbsp;Pulmonary Arterial Hypertension Market, By Region

6.1&nbsp;&nbsp;&nbsp; Key regional trends

6.2&nbsp;&nbsp;&nbsp; North America

6.2.1&nbsp;&nbsp;&nbsp; Market size, by country, 2016 - 2027 (USD Million)

6.2.2&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.2.3&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.2.4&nbsp;&nbsp;&nbsp; U.S.

6.2.4.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.2.4.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.2.5&nbsp;&nbsp;&nbsp; Canada

6.2.5.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.2.5.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.3&nbsp;&nbsp;&nbsp; Europe

6.3.1&nbsp;&nbsp;&nbsp; Market size, by country, 2016 - 2027 (USD Million)

6.3.2&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.3.3&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.3.4&nbsp;&nbsp;&nbsp; Germany

6.3.4.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.3.4.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.3.5&nbsp;&nbsp;&nbsp; UK

6.3.5.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.3.5.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.3.6&nbsp;&nbsp;&nbsp; France

6.3.6.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.3.6.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.3.7&nbsp;&nbsp;&nbsp; Spain

6.3.7.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.3.7.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.3.8&nbsp;&nbsp;&nbsp; Italy

6.3.8.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.3.8.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.4&nbsp;&nbsp;&nbsp; Asia Pacific

6.4.1&nbsp;&nbsp;&nbsp; Market size, by country, 2016 - 2027 (USD Million)

6.4.2&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.4.3&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.4.4&nbsp;&nbsp;&nbsp; Japan

6.4.4.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.4.4.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.4.5&nbsp;&nbsp;&nbsp; China

6.4.5.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.4.5.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.4.6&nbsp;&nbsp;&nbsp; India

6.4.6.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.4.6.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.4.7&nbsp;&nbsp;&nbsp; Australia

6.4.7.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.4.7.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.4.8&nbsp;&nbsp;&nbsp; South Korea

6.4.8.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.4.8.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.5&nbsp;&nbsp;&nbsp; Latin America

6.5.1&nbsp;&nbsp;&nbsp; Market size, by country, 2016 - 2027 (USD Million)

6.5.2&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.5.3&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.5.4&nbsp;&nbsp;&nbsp; Brazil

6.5.4.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.5.4.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.5.5&nbsp;&nbsp;&nbsp; Mexico

6.5.5.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.5.5.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.5.6&nbsp;&nbsp;&nbsp; Argentina

6.5.6.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.5.6.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.6&nbsp;&nbsp;&nbsp; Middle East and Africa

6.6.1&nbsp;&nbsp;&nbsp; Market size, by country, 2016 - 2027 (USD Million)

6.6.2&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.6.3&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.6.4&nbsp;&nbsp;&nbsp; South Africa

6.6.4.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.6.4.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.6.5&nbsp;&nbsp;&nbsp; Saudi Arabia

6.6.5.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.6.5.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

6.6.6&nbsp;&nbsp;&nbsp; UAE

6.6.6.1&nbsp;&nbsp;&nbsp; Market size, by drug class, 2016 - 2027 (USD Million)

6.6.6.2&nbsp;&nbsp;&nbsp; Market size, by route of administration, 2016 &ndash; 2027 (USD Million)

Chapter 7&nbsp;&nbsp;&nbsp;Company Profiles

7.1&nbsp;&nbsp;&nbsp; Competitive dashboard, 2020

7.2&nbsp;&nbsp;&nbsp; Bayer AG

7.2.1&nbsp;&nbsp;&nbsp; Business overview

7.2.2&nbsp;&nbsp;&nbsp; Financial data

7.2.3&nbsp;&nbsp;&nbsp; Product landscape

7.2.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.2.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.3&nbsp;&nbsp;&nbsp; Eli Lilly and Company

7.3.1&nbsp;&nbsp;&nbsp; Business overview

7.3.2&nbsp;&nbsp;&nbsp; Financial data

7.3.3&nbsp;&nbsp;&nbsp; Product landscape

7.3.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.3.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.4&nbsp;&nbsp;&nbsp; Gilead Sciences, Inc.

7.4.1&nbsp;&nbsp;&nbsp; Business overview

7.4.2&nbsp;&nbsp;&nbsp; Financial data

7.4.3&nbsp;&nbsp;&nbsp; Product landscape

7.4.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.4.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.5&nbsp;&nbsp;&nbsp; GlaxoSmithKline plc.

7.5.1&nbsp;&nbsp;&nbsp; Business overview

7.5.2&nbsp;&nbsp;&nbsp; Financial data

7.5.3&nbsp;&nbsp;&nbsp; Product landscape

7.5.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.5.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.6&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

7.6.1&nbsp;&nbsp;&nbsp; Business overview

7.6.2&nbsp;&nbsp;&nbsp; Financial data

7.6.3&nbsp;&nbsp;&nbsp; Product landscape

7.6.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.6.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.7&nbsp;&nbsp;&nbsp; Pfizer, Inc.

7.7.1&nbsp;&nbsp;&nbsp; Business overview

7.7.2&nbsp;&nbsp;&nbsp; Financial data

7.7.3&nbsp;&nbsp;&nbsp; Product landscape

7.7.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.7.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.8&nbsp;&nbsp;&nbsp; United Therapeutics Corporation

7.8.1&nbsp;&nbsp;&nbsp; Business overview

7.8.2&nbsp;&nbsp;&nbsp; Financial data

7.8.3&nbsp;&nbsp;&nbsp; Product landscape

7.8.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.8.5&nbsp;&nbsp;&nbsp; SWOT analysis 
&nbsp;

Pulmonary Arterial Hypertension Market

Get a free sample of this report

Industries

Information

Link

Global Headquarters